JAAD International

Article info Publication history Accepted: April 6, 2023 Received: March 20, 2023 Publication stage In Press Accepted Manuscript Footnotes Funding source: Boehringer Ingelheim Canada funded the study. Patient consent: not applicable Conflict of interest: •McMaster University (Jean-Eric Tarride as Principal Investigator) has received a grant from Boehringer Ingelheim for this research.

This paper is only available as a PDF. To read, Please Download here.

Consent for the publication of all patient photographs and medical information was provided by the authors at the time of article submission to the journal stating that all patients gave consent for their photographs and medical information to be published in print and online and with the understanding that this information may be publicly available.

Discrepancies have been noted between clinical and histological diagnosis of vascular malformations. To evaluate the effectiveness of the International Society for the Study of Vascular Anomalies (ISSVA) classification in diagnosing benign vascular anomalies (VA) based on clinical and (immuno) histological parameters, focusing on lymphatic differentiation and vascular proliferation.

Teledermoscopy accuracy has been examined in experimental settings and is recommended for primary care despite lacking real-world implementation evidence. A teledermoscopy service has been provided in Estonia since 2013 where lesions are evaluated based on the patient’s or general practitioner’s suggestion. Management plan and diagnostic accuracy of a real-world store-and-forward teledermoscopy service for melanoma diagnosis were evaluated.

Article info Publication history Accepted: February 19, 2023 Received: January 15, 2023 Publication stage In Press Accepted Manuscript Footnotes IRB approval was not required for this study. Patient consent: Not applicable Funding sources: The authors would like to thank the National Psoriasis Foundation for support of this study.

Conflict of Interest: The authors have declared that no conflict of interest exists. Acknowledgements: Data for this project were accessed using the Stanford Center for Population Health Sciences Data Core. The PHS Data Core is supported by a National Institutes of Health National Center for Advancing Translational Science Clinical and Translational Science Award (UL1TR003142) and from Internal Stanford funding.

Footnotes Funding sources: Herbert Irving Comprehensive Cancer Center Intra/Inter-Programmatic Pilot Program. Conflicts of Interest: LJG has served as an investigator for and/or received research support from Helsinn Group, J&J, Mallinckrodt, Kyowa Kirin, Soligenix, Innate, Merck, BMS, and Stratpharma; on the speakers’ bureau for Helsinn Group and J&J; and on the scientific advisory board for Helsinn Group, J&J, Mallinckrodt, Sanofi, Regeneron, and Kyowa Kirin.

Department of Dermatology, State University of New York Downstate Health Sciences, University, Brooklyn, New York New York Medical College, Department of Dermatology, Valhalla, New York NYC Health + Hospitals/South Brooklyn Health, Ruth Bader Ginsburg Hospital, Department of Medicine, Brooklyn, New York NYC Health + Hospitals/Metropolitan Medical Center, Department of Dermatology, New York, New York

Background Policymakers and payers are reevaluating the temporary telehealth flexibilities granted during the COVID-19 public health emergency, which will shape future teledermatology utilization. Objective To summarize the recently expanded telehealth flexibilities in the United States, projected changes, and corresponding implications for dermatologists. Methods Narrative review of the literature, United States policies and regulations, and white paper reports.